MREO

MREO

USD

Mereo BioPharma Group plc American Depositary Shares

$1.780-0.050 (-2.732%)

リアルタイム価格

Healthcare
バイオテクノロジー
英国

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$1.830

高値

$1.880

安値

$1.780

出来高

1.12M

企業ファンダメンタルズ

時価総額

283.2M

業種

バイオテクノロジー

United Kingdom

取引統計

平均出来高

1.32M

取引所

NCM

通貨

USD

52週レンジ

安値 $1.47現在値 $1.780高値 $4.395

関連ニュース

PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO

Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc ("Mereo" or the "Company") (NASDAQ: MREO). Such investors...

もっと見る
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
Analyst Upgrades

JP Morgan Maintains Overweight on Mereo BioPharma Group, Raises Price Target to $8

JP Morgan analyst Priyanka Grover maintains Mereo BioPharma Group with a Overweight and raises the price target from $7 to $8.

もっと見る
JP Morgan Maintains Overweight on Mereo BioPharma Group, Raises Price Target to $8
PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO

Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc ("Mereo" or the "Company") (NASDAQ: MREO). Such investors...

もっと見る
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
BusinessWire

āshibio Expands Clinical Pipeline with Vantictumab, a First-In-Class Antibody for Autosomal Dominant Osteopetrosis Type 2

- Company's second clinical-stage asset licensed from Mereo Biopharma based on novel insights generated in a mouse model of osteopetrosis - - āshibio has exclusive license to develop and commercialize vantictumab

もっと見る
āshibio Expands Clinical Pipeline with Vantictumab, a First-In-Class Antibody for Autosomal Dominant Osteopetrosis Type 2
GlobeNewswire

Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights

Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta expected around year-end 2025 Cash of $56.1 million as of June 30, 2025, expected to support operations into 2027 LONDON, Aug. 12,

もっと見る
Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights
PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO

Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc ("Mereo" or the "Company") (NASDAQ: MREO). Such investors...